Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.49 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28382945 | 0.91 | TAAR1 (0.44) | LTA4HPPARGL3MBTL1HPGDPPARD | |
| SCHEMBL13679030 | 0.88 | TAAR1 (0.47) | PPARGTDP1L3MBTL1PPARDPPARA | |
| SCHEMBL15186253 | 0.86 | LTA4H (0.50) | LTA4HTSHRNPC1HPGDCRHBP | |
| SCHEMBL8259799 | 0.85 | PPARG (0.46) | PPARGPPARDPPARA | |
| SCHEMBL14431591 | 0.82 | PPARG (0.38) | LTA4HPPARGL3MBTL1RAB9APPARD | |
| SCHEMBL14431706 | 0.82 | SLC6A4 (0.47) | NPC1RAB9AMAOB | |
| SCHEMBL2412893 | 0.81 | LTA4H (0.47) | LTA4HPPARGPPARD | |
| SCHEMBL8262759 | 0.81 | PPARG (0.41) | LTA4HPPARGL3MBTL1RAB9APPARD | |
| SCHEMBL20439168 | 0.81 | LTA4H (0.53) | LTA4HTSHRTDP1L3MBTL1NPC1 | |
| SCHEMBL10357434 | 0.80 | TAAR1 (0.37) | LTA4HPPARGTSHRPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7652061-B2 | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1638963-B1 | N-ACYL NITROGEN HETEROCYCLES AS LIGANDS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | NOVARTIS AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | GARRETT CHRISTINE E | 2008-09-11 | — | — | US | disclosed |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | COHEN DAVID SAUL | 2008-06-05 | — | — | US | disclosed |
| US-20070299047-A1 | Combination of Organic Compounds | MAHER WILLIAM | 2007-12-27 | — | — | US | disclosed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006029349-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | LTA4H 1212/4885PPARG 1/4885TSHR 972/4885 |
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | LTA4H 1319/4885PPARG 1/4885TSHR 1631/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | LTA4H 1212/4885PPARG 1/4885TSHR 972/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | LTA4H 1212/4885PPARG 1/4885TSHR 972/4885 |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | PPARG, PPARA, PPARD | LTA4H 2155/4885PPARG 1/4885TSHR 1281/4885 |
| US-20070299047-A1 | Combination of Organic Compounds | GLP1R, PPARG, GCGR | LTA4H 1798/4885PPARG 2/4885TSHR 389/4885 |
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | PPARA, PPARG, PPARD | LTA4H 1822/4885PPARG 2/4885TSHR 407/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | LTA4H 2450/4885PPARG 1/4885TSHR 1998/4885 |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | PPARA, PPARD, PPARG | LTA4H 1844/4885PPARG 3/4885TSHR 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.